BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40:148-156. [PMID: 15770398 DOI: 10.1007/s00535-004-1519-2] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Fujiwara N, Liu P, Athuluri-divakar SK, Zhu S, Hoshida Y. Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 3-25. [DOI: 10.1007/978-3-030-21540-8_1] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nagaoki Y, Aikata H, Nakano N, Shinohara F, Nakamura Y, Hatooka M, Morio K, Kan H, Fujino H, Kobayashi T, Fukuhara T, Masaki K, Ono A, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Kawakami Y, Ochi H, Chayama K; The Hiroshima Liver Study Group. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study: Hepatoma after HCV eradication. Journal of Gastroenterology and Hepatology 2016;31:1009-15. [DOI: 10.1111/jgh.13236] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
3 Nosotti L, D'Arca T, Marignani M, Balducci G. Hepatocellular Carcinoma in a non-Cirrhotic Liver of a HCV-Positive Woman with Sustained Viral Response. Mediterr J Hematol Infect Dis 2011;3:e2011050. [PMID: 22110900 DOI: 10.4084/MJHID.2011.050] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Ogata F, Akuta N, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens. J Med Virol 2018;90:1087-93. [PMID: 29427443 DOI: 10.1002/jmv.25047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol. 2011;46:799-808. [PMID: 21373851 DOI: 10.1007/s00535-011-0384-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
6 Otoguro T, Tanaka T, Kasai H, Yamashita A, Moriishi K. Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity. Microbiol Immunol 2016;60:740-53. [PMID: 27797115 DOI: 10.1111/1348-0421.12448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19(18): 2793-2798 [PMID: 23687416 DOI: 10.3748/wjg.v19.i18.2793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
8 Teixeira AC, Mente ED, Cantao CAB, Sankarankutty AK, Souza FF, Motta TC, Monsignore L, Junior JE, Muglia VF, Abud DG, Peria FM, Silva OC, de Lourdes Candolo Martinelli A. Clinical Characteristics of 130 Patients With Hepatocellular Carcinoma Followed at a Tertiary Hospital From Brazil. World J Oncol 2012;3:165-72. [PMID: 29147300 DOI: 10.4021/wjon549w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Fukushima N, Kuromatsu R, Arinaga-Hino T, Ando E, Takata A, Sumie S, Nakano M, Kawaguchi T, Ide T, Torimura T. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol Res. 2010;40:911-922. [PMID: 20887596 DOI: 10.1111/j.1872-034x.2010.00699.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
10 Toyoda H, Tada T, Takaguchi K, Senoh T, Shimada N, Hiraoka A, Michitaka K, Ishikawa T, Kumada T. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. J Viral Hepat 2017;24:472-6. [PMID: 27983762 DOI: 10.1111/jvh.12665] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
11 El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016;64:130-137. [PMID: 26946190 DOI: 10.1002/hep.28535] [Cited by in Crossref: 232] [Cited by in F6Publishing: 213] [Article Influence: 38.7] [Reference Citation Analysis]
12 da Costa Ferreira S, de Vasconcelos Carneiro M, Souza FF, Teixeira AC, Villanova MG, de Castro Figueiredo JF, Passos ADC, Ramalho LNZ, Zucoloto S, Martinelli ADLC. Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon. The Brazilian Journal of Infectious Diseases 2010;14:330-4. [DOI: 10.1016/s1413-8670(10)70070-2] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
13 Okimoto S, Kobayashi T, Kuroda S, Ishiyama K, Ide K, Ohira M, Tahara H, Shimizu S, Iwako H, Hamaoka M, Honmyo N, Yamaguchi M, Ohdan H. Prediction of recurrence following hepatectomy in patients with hepatitis C virus infection-related hepatocellular carcinoma who achieved a sustained virological response. Hepatol Res 2017;47:1186-95. [PMID: 28326662 DOI: 10.1111/hepr.12896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 Yasuda S, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Toyoda H, Kumada T, Hirooka Y, Goto H. Substitutions in interferon sensitivity-determining region and hepatocarcinogenesis after hepatitis C virus eradication. J Gastroenterol Hepatol 2018;33:1904-11. [PMID: 29744922 DOI: 10.1111/jgh.14280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Bandiera S, Billie Bian C, Hoshida Y, Baumert TF, Zeisel MB. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol. 2016;20:99-105. [PMID: 27741441 DOI: 10.1016/j.coviro.2016.09.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
16 Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med 2017;15:52. [PMID: 28288626 DOI: 10.1186/s12916-017-0815-7] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 17.4] [Reference Citation Analysis]
17 George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729-738. [PMID: 19072828 DOI: 10.1002/hep.22694] [Cited by in Crossref: 287] [Cited by in F6Publishing: 251] [Article Influence: 22.1] [Reference Citation Analysis]
18 Tamura Y, Yamagiwa S, Aoki Y, Kurita S, Suda T, Ohkoshi S, Nomoto M, Aoyagi Y. Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci. 2009;54:2530-2537. [PMID: 19093203 DOI: 10.1007/s10620-008-0642-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
19 Finkelmeier F, Dultz G, Peiffer KH, Kronenberger B, Krauss F, Zeuzem S, Sarrazin C, Vermehren J, Waidmann O. Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals. Liver Cancer 2018;7:190-204. [PMID: 29888208 DOI: 10.1159/000486812] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
20 Kaito M, Horiike S, Tanaka H, Fujita N, Adachi Y. Accumulation of 8-nitroguanine in the liver of chronic hepatitis C patients without sustained virological response after completion of interferon therapy. J Gastroenterol 2006;41:713-4. [PMID: 16933012 DOI: 10.1007/s00535-006-1832-z] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
21 Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt VR. Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection. Mediterr J Hematol Infect Dis. 2017;9:e2017019. [PMID: 28293407 DOI: 10.4084/mjhid.2017.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
22 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Hirooka M, Abe M, Hiasa Y. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol Res. 2019;49:136-146. [PMID: 30335208 DOI: 10.1111/hepr.13278] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
23 Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol 2011; 17(4): 493-498 [PMID: 21274379 DOI: 10.3748/wjg.v17.i4.493] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
24 Akuta N, Suzuki F, Kobayashi M, Sezaki H, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. J Clin Microbiol 2015;53:3039-41. [PMID: 26135874 DOI: 10.1128/JCM.01457-15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
25 Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother 2017;18:1867-74. [PMID: 29086615 DOI: 10.1080/14656566.2017.1400010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
26 Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485 [PMID: 29632428 DOI: 10.3748/wjg.v24.i13.1478] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
27 Miyasaka A, Yoshida Y, Suzuki A, Sawara K, Takikawa Y. A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination. Int J Gen Med 2021;14:8935-43. [PMID: 34866934 DOI: 10.2147/IJGM.S344492] [Reference Citation Analysis]
28 Toyoda H, Tada T, Tsuji K, Hiraoka A, Tachi Y, Itobayashi E, Takaguchi K, Senoh T, Takizawa D, Ishikawa T, Kumada T. Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan: Outcomes of HCC after SVR. Hepatol Res 2016;46:734-42. [DOI: 10.1111/hepr.12613] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
29 Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C; HENCORE Group. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007;14:556-63. [PMID: 17650289 DOI: 10.1111/j.1365-2893.2006.00829.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
30 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC. J Hepatocell Carcinoma 2020;7:347-60. [PMID: 33299823 DOI: 10.2147/JHC.S279657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Ogasawara S, Akiba J, Nakayama M, Kusano H, Yano H. Antiproliferative effect of ME3738, a derivative of soyasapogenol, on hepatocellular carcinoma cell lines in vitro and in vivo. Biomed Rep 2016;5:731-6. [PMID: 28105340 DOI: 10.3892/br.2016.792] [Reference Citation Analysis]
33 Yamashita N, Ohho A, Yamasaki A, Kurokawa M, Kotoh K, Kajiwara E. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol. 2014;49:1504-1513. [PMID: 24317936 DOI: 10.1007/s00535-013-0921-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
34 Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:105-114. [PMID: 26157746 DOI: 10.3350/cmh.2015.21.2.105] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 11.4] [Reference Citation Analysis]
35 Rutledge SM, Zheng H, Li DK, Chung RT. No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. Hepatoma Res 2019;5:31. [PMID: 31453368 DOI: 10.20517/2394-5079.2019.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
36 Toyoda H, Kumada T. ‘YES, NOW YOU ARE FREE FROM CHRONIC HCV INFECTION, BUT . . .’. Journal of Gastroenterology and Hepatology 2006;21:9-10. [DOI: 10.1111/j.1440-1746.2005.04207.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis. 2010;42:341-347. [PMID: 19828388 DOI: 10.1016/j.dld.2009.09.002] [Cited by in Crossref: 100] [Cited by in F6Publishing: 93] [Article Influence: 7.7] [Reference Citation Analysis]
38 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
39 Prenner S, Kulik L. HCC: Where Does HCV Therapy Play a Role? Curr Hepatology Rep 2016;15:17-25. [DOI: 10.1007/s11901-016-0292-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Mashiba T, Joko K, Kurosaki M, Ochi H, Osaki Y, Kojima Y, Nakata R, Goto T, Takehiro A, Kimura H. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS One. 2018;13:e0194704. [PMID: 29659591 DOI: 10.1371/journal.pone.0194704] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
41 Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat 2011;18:1-7. [PMID: 20796208 DOI: 10.1111/j.1365-2893.2010.01366.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
42 Kudo M. Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response. Liver Cancer 2016;5:155-61. [PMID: 27493891 DOI: 10.1159/000443563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Abe K, Wakabayashi H, Nakayama H, Suzuki T, Kuroda M, Yoshida N, Tojo J, Kogure A, Rai T, Saito H, Mukai S, Fujita M, Hayashi M, Takahashi A, Ohira H. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. PLoS One 2020;15:e0243473. [PMID: 33284844 DOI: 10.1371/journal.pone.0243473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Grosfeld JL, Otte J. Liver Tumors in Children. In: Carachi R, Grosfeld JL, Azmy AF, editors. The Surgery of Childhood Tumors. Berlin: Springer Berlin Heidelberg; 2008. pp. 227-60. [DOI: 10.1007/978-3-540-29734-5_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Masetti C, Lionetti R, Lupo M, Siciliano M, Giannelli V, Ponziani FR, Teti E, Dell'unto C, Francioso S, Brega A, Montalbano M, Visco-comandini U, Taibi C, Galati G, Vespasiani Gentilucci U, Picardi A, Andreoni M, Pompili M, Pellicelli AM, D'offizi G, Gasbarrini A, De Santis A, Angelico M. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2018;25:1493-500. [DOI: 10.1111/jvh.12982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
46 Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy. J Gastroenterol Hepatol. 2014;29:137-143. [PMID: 24117602 DOI: 10.1111/jgh.12401] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
47 D'ambrosio R, Colombo M. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression? Liver Int 2016;36:783-90. [DOI: 10.1111/liv.13106] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
48 Sasaki R, Yamasaki K, Abiru S, Komori A, Nagaoka S, Saeki A, Hashimoto S, Bekki S, Kugiyama Y, Kuno A, Korenaga M, Togayachi A, Ocho M, Mizokami M, Narimatsu H, Ichikawa T, Nakao K, Yatsuhashi H. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. PLoS One 2015;10:e0129053. [PMID: 26070204 DOI: 10.1371/journal.pone.0129053] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
49 Hidaka M, Takatsuki M, Soyama A, Miyaaki H, Ichikawa T, Nakao K, Kanematsu T, Eguchi S. Living donor liver transplantation from a donor previously treated with interferon for hepatitis C virus: a case report. J Med Case Rep 2011;5:276. [PMID: 21722402 DOI: 10.1186/1752-1947-5-276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Ito T. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015;30:1183-1189. [PMID: 25678094 DOI: 10.1111/jgh.12915] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 9.7] [Reference Citation Analysis]
51 Takemura K, Takizawa E, Tamori A, Nakamae M, Kubota H, Uchida-Kobayashi S, Enomoto M, Kawada N, Hino M. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. Int J Mol Sci 2020;21:E4517. [PMID: 32630450 DOI: 10.3390/ijms21124517] [Reference Citation Analysis]
52 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C: AFP predicts HCC development in SVR patients. Hepatol Res 2017;47:1021-31. [DOI: 10.1111/hepr.12839] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
53 Tholey DM, Ahn J. Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma. Gastroenterology Clinics of North America 2015;44:761-73. [DOI: 10.1016/j.gtc.2015.07.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
54 Muzica CM, Stanciu C, Huiban L, Singeap AM, Sfarti C, Zenovia S, Cojocariu C, Trifan A. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol 2020; 26(43): 6770-6781 [PMID: 33268960 DOI: 10.3748/wjg.v26.i43.6770] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
55 Goossens N, Nakagawa S, Hoshida Y. Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol 2015; 21(36): 10262-10273 [PMID: 26420954 DOI: 10.3748/wjg.v21.i36.10262] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
56 Hamada K, Saitoh S, Nishino N, Fukushima D, Horikawa Y, Nishida S, Honda M. Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response. PLoS One 2018;13:e0195173. [PMID: 29672518 DOI: 10.1371/journal.pone.0195173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
57 Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007;27:186-191. [PMID: 17311612 DOI: 10.1111/j.1478-3231.2006.01406.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
58 Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
59 Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. Eur J Gastroenterol Hepatol. 2013;25:798-805. [PMID: 23395996 DOI: 10.1097/meg.0b013e32835eb8bf] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
60 Sato S, Genda T, Ichida T, Amano N, Sato S, Murata A, Tsuzura H, Narita Y, Kanemitsu Y, Hirano K, Shimada Y, Iijima K, Wada R, Nagahara A, Watanabe S. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. Int J Mol Sci. 2016;17. [PMID: 27999409 DOI: 10.3390/ijms17122143] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
61 Osawa M, Saitoh S, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kinowaki K, Fujii T, Fukusato T, Kondo F, Kumada H. Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection. Intern Med 2017;56:3033-40. [PMID: 28943584 DOI: 10.2169/internalmedicine.9021-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
62 Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncol Lett. 2020;19:2205-2212. [PMID: 32194718 DOI: 10.3892/ol.2020.11341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
63 Kawaguchi T, Ide T, Koga H, Kondo R, Miyajima I, Arinaga-Hino T, Kuwahara R, Amano K, Niizeki T, Nakano M, Kuromatsu R, Torimura T. Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C. Clin J Gastroenterol 2018;11:69-74. [PMID: 29082453 DOI: 10.1007/s12328-017-0789-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
64 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol 2011;83:1016-22. [DOI: 10.1002/jmv.22094] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
65 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
66 Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015;45:152-161. [PMID: 25052449 DOI: 10.1111/hepr.12393] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
67 Noh R, Lee DH, Kwon BW, Kim YH, Kim SB, Song IH. Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection. Gastroenterol Res Pract. 2016;2016:7476231. [PMID: 27656205 DOI: 10.1155/2016/7476231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
68 Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152:1578-1587. [PMID: 28344022 DOI: 10.1053/j.gastro.2017.03.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
69 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
70 Toyoda H, Tada T, Yasuda S, Mizuno K, Ito T, Kumada T. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response. Clin Infect Dis 2020;70:1208-14. [PMID: 31056696 DOI: 10.1093/cid/ciz359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
71 Huang CF, Chuang WL, Yu ML. Chronic hepatitis C infection in the elderly. Kaohsiung J Med Sci 2011;27:533-7. [PMID: 22208535 DOI: 10.1016/j.kjms.2011.10.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
72 Matsuura T, Ohfuji S, Enomoto M, Tamori A, Kubo S, Kioka K, Kawada N, Fukushima W. Risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients-Relationship to smoking and alcohol. JGH Open 2020;4:867-75. [PMID: 33102757 DOI: 10.1002/jgh3.12331] [Reference Citation Analysis]
73 Tang S, Yue M, Wang J, Su J, Yu R, Zhou D, Xu K, Cai L, Zhang Y, Wang J. Association of genetic variants in estrogen receptor α with HCV infection susceptibility and viral clearance in a high-risk Chinese population. Eur J Clin Microbiol Infect Dis 2014;33:999-1010. [PMID: 24395301 DOI: 10.1007/s10096-013-2038-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
74 Nikiforuk AM, Karim ME, Patrick DM, Jassem AN. Influence of chronic hepatitis C infection on the monocyte-to-platelet ratio: data analysis from the National Health and Nutrition Examination Survey (2009-2016). BMC Public Health 2021;21:1388. [PMID: 34256707 DOI: 10.1186/s12889-021-11267-w] [Reference Citation Analysis]
75 Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, Shiga J, Takikawa H. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13(39): 5180-5187 [PMID: 17876888 DOI: 10.3748/wjg.v13.i39.5180] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
76 Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, Butt ZA, Samji H, Cook D, Yu A, Alvarez M, Tyndall M, Krajden M. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66:504-513. [PMID: 27818234 DOI: 10.1016/j.jhep.2016.10.028] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 8.8] [Reference Citation Analysis]
77 Tong MJ, Theodoro CF, Salvo RT. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance: Late onset of HCC after HCV clearance. Journal of Digestive Diseases 2018;19:411-20. [DOI: 10.1111/1751-2980.12615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
78 Asahina Y; Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis. Hepatol Res 2020;50:775-90. [DOI: 10.1111/hepr.13501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
79 Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci. 2011;56:1853-1861. [PMID: 21374066 DOI: 10.1007/s10620-011-1621-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
80 Tahata Y, Sakamori R, Urabe A, Yamada R, Ohkawa K, Hiramatsu N, Hagiwara H, Oshita M, Hijioka T, Tamura S, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Hepatocellular carcinoma occurrence does not differ between interferon‐based and interferon‐free treatment with liver histological assessment. Hepatol Res 2020;50:313-20. [DOI: 10.1111/hepr.13454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
81 van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017;66:485-93. [PMID: 27780714 DOI: 10.1016/j.jhep.2016.10.017] [Cited by in Crossref: 148] [Cited by in F6Publishing: 137] [Article Influence: 24.7] [Reference Citation Analysis]
82 Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 2015;121:2874-82. [PMID: 26079399 DOI: 10.1002/cncr.29528] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 6.7] [Reference Citation Analysis]
83 Tachi Y, Hirai T, Toyoda H, Tada T, Hayashi K, Honda T, Ishigami M, Goto H, Kumada T. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One 2015;10:e0133515. [PMID: 26214180 DOI: 10.1371/journal.pone.0133515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
84 Tachi Y, Hirai T, Ishizu Y, Honda T, Kuzuya T, Hayashi K, Ishigami M, Goto H. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. J Gastroenterol Hepatol 2016;31:1001-8. [PMID: 27123974 DOI: 10.1111/jgh.13245] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
85 Tamori A, Hayashi T, Shinzaki M, Kobayashi S, Iwai S, Enomoto M, Morikawa H, Sakaguchi H, Shiomi S, Takemura S. Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol. 2009;81:1009-1014. [PMID: 19382258 DOI: 10.1002/jmv.21488] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]